Neuropathy impairment and nutritional status with eplontersen in patients with hereditary transthyretin-mediated amyloidosis

被引:0
|
作者
Wixner, Jonas [1 ,2 ]
Conceicao, Isabel [3 ]
Berk, John [4 ]
Adams, David [5 ]
Polydefkis, Michael [6 ]
Shahram, Attarian [7 ]
Gillmore, Julian D. [8 ,9 ]
Dyck, P. James B. [10 ]
Coelho, Teresa [11 ]
Chen, Jersey [12 ]
Hardy, Elise [12 ]
Kwoh, Jesse [13 ]
Natman, Jonatan [12 ]
Cruz, Marcia Waddington [13 ]
机构
[1] Umea Univ, Umea, Sweden
[2] Umea Univ, Dept Publ Hlth & Clin Med, Umea, Sweden
[3] Governo Republ Portuguesa, Lisbon, Portugal
[4] Boston Univ, Boston, MA USA
[5] Republ Francaise, Paris, France
[6] Johns Hopkins Univ, Baltimore, MD USA
[7] Timone Univ Hosp, Referral Ctr Neuromuscular Dis & ALS, APHM, Marseille, France
[8] Euro NMD, Filnemus, Marseille, France
[9] Univ London, London, England
[10] Mayo Fdn Med Educ & Res, Rochester, MN USA
[11] Ctr Hosp Univ Santo Antonio, Unidade Corino Andrade, Porto, Portugal
[12] AstraZeneca, BioPharmaceut R, Gaithersburg, MD USA
[13] Ionis Pharmaceut Inc, Clin Dev, Carlsbad, CA USA
关键词
D O I
暂无
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
174
引用
收藏
页码:S68 / S68
页数:1
相关论文
共 50 条
  • [41] Kidney Function And Proteinuria With Eplontersen Treatment For Hereditary Transthyretin Amyloidosis
    Maurer, Mathew s
    Gillmore, Julian D.
    Berk, John l
    Masri, Ahmad
    DA Silva, Moises dias
    Kwoh, Jesse
    Littl, Dustin j
    Natman, Jonatan
    Zhou, Wunan
    Waddington-cruz, Marcia
    JOURNAL OF CARDIAC FAILURE, 2025, 31 (01) : 346 - 347
  • [42] IDENTIFYING MIXED PHENOTYPE: EVALUATING THE PRESENCE OF POLYNEUROPATHY IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH CARDIOMYOPATHY
    Grogan, Martha
    Hawkins, Philip
    Kristen, Arnt
    Berk, John
    Suhr, Ole B.
    Lin, Hollis
    Merkel, Madeline
    McManus, Anastasia
    Powell, Christine
    Vest, John
    Karsten, Verena
    Judge, Daniel
    MUSCLE & NERVE, 2020, 62 : S107 - S107
  • [43] Identifying Mixed Phenotype: Evaluating the Presence of Polyneuropathy in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Cardiomyopathy
    Merkel, Madeline
    Grogan, Martha
    Hawkins, Philip N.
    Kristen, Arnt V.
    Berk, John L.
    Suhr, Ole B.
    Lin, Hollis
    McManus, Anastasia
    Powell, Christine
    Vest, John
    Karsten, Verena
    Judge, Daniel P.
    NEUROLOGY, 2020, 94 (15)
  • [44] Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial
    Adams, David
    Tournev, Ivailo L.
    Taylor, Mark S.
    Coelho, Teresa
    Plante-Bordeneuve, Violaine
    Berk, John L.
    Gonzalez-Duarte, Alejandra
    Gillmore, Julian D.
    Low, Soon-Chai
    Sekijima, Yoshiki
    Obici, Laura
    Chen, Chongshu
    Badri, Prajakta
    Arum, Seth M.
    Vest, John
    Polydefkis, Michael
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2023, 30 (01): : 18 - 26
  • [45] Long-term integrated safety of patisiran in patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Gillmore, J.
    Berk, J.
    Dispenzieri, A.
    Polydefkis, M.
    Gonzalez-Duarte, A.
    Sekijima, Y.
    Sweetser, M. T.
    Arum, S.
    Wang, J. J.
    White, M. T.
    Maurer, M.
    EUROPEAN HEART JOURNAL, 2020, 41 : 2129 - 2129
  • [46] Impact of Vutrisiran on Quality of Life and Physical Function in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy
    Laura Obici
    Senda Ajroud-Driss
    Kon-Ping Lin
    John L. Berk
    Julian D. Gillmore
    Parag Kale
    Haruki Koike
    David Danese
    Emre Aldinc
    Chongshu Chen
    John Vest
    David Adams
    Neurology and Therapy, 2023, 12 (5) : 1759 - 1775
  • [47] Pharmacokinetics of Patisiran, the First Approved RNA Interference Therapy in Patients With Hereditary Transthyretin-Mediated Amyloidosis
    Zhang, Xiaoping
    Goel, Varun
    Robbie, Gabriel J.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 60 (05): : 573 - 585
  • [48] Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Garcia-Pavia, Pablo
    Grogan, Martha
    Kale, Parag
    Berk, John L.
    Maurer, Mathew S.
    Conceicao, Isabel
    Di Carli, Marcelo
    Solomon, Scott D.
    Chen, Chongshu
    Yureneva, Elena
    Vest, John
    Gillmore, Julian D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (02) : 397 - 410
  • [49] Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
    Dixon, Stacy
    Kang, Xuan
    Quan, Dianna
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2023, 19 : 973 - 981
  • [50] Treatment with patisiran of a patient with hereditary transthyretin-mediated amyloidosis with stage 3 polyneuropathy
    Mueschen, Lars H.
    Koerner, Gudrun
    Gingele, Stefan
    Haenselmann, Anja
    Bavendiek, Udo
    Skripuletz, Thomas
    MUSCLE & NERVE, 2021, 64 (03) : E11 - E13